KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Gross Margin (2018 - 2025)

Adaptive Biotechnologies' Gross Margin history spans 8 years, with the latest figure at 98.23% for Q4 2025.

  • For Q4 2025, Gross Margin rose 2726.0% year-over-year to 98.23%; the TTM value through Dec 2025 reached 74.24%, up 1451.0%, while the annual FY2025 figure was 74.24%, 1451.0% up from the prior year.
  • Gross Margin for Q4 2025 was 98.23% at Adaptive Biotechnologies, up from 62.64% in the prior quarter.
  • Across five years, Gross Margin topped out at 151.33% in Q4 2021 and bottomed at 210.03% in Q2 2023.
  • The 5-year median for Gross Margin is 58.96% (2024), against an average of 53.33%.
  • The largest annual shift saw Gross Margin plummeted -30929bps in 2023 before it soared 26530bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 151.33% in 2021, then plummeted by -46bps to 81.91% in 2022, then tumbled by -36bps to 52.15% in 2023, then surged by 36bps to 70.97% in 2024, then surged by 38bps to 98.23% in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Gross Margin are 98.23% (Q4 2025), 62.64% (Q3 2025), and 69.43% (Q2 2025).